First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts

Summary

This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of topically applied CLS003 in healthy subjects with cutaneous warts.

Timeline

Start

2014-03

Primary completion

2014-04

Completion

—

Drugs

Indications